Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 60

Sort by

Sort Order Select

Journal Articles

Brentuximab vedotin, nivolumab, doxorubicin, and dacarbazine for advanced-stage classical Hodgkin lymphoma

Blood (2025) 145 (3): 290–299.

https://doi.org/10.1182/blood.2024024681

Published: 2025

Includes: Supplemental data

Journal Articles

Impact of Timing of Acute Graft-Versus-Host-Disease on Incidence of Thrombotic Microangiopathy after Hematopoietic Stem Cell Transplantation

Udit Nangia, Leland Metheny, Neeraj Mahajan

Blood (2024) 144 (Supplement 1): 1241.

https://doi.org/10.1182/blood-2024-202257

Published: 2024

Journal Articles

Real-World Trends of Cytokine Release Syndrome and Neurologic Events, and Pattern of Their Management Among Patients Receiving Axicabtagene Ciloleucel for Relapsed or Refractory (r/r) Large B-Cell Lymphoma (LBCL) in the US: A CIBMTR Report

Jiasheng Wang, Shakthi Bhaskar, Babatunde Adedokun, Olalekan O. Oluwole, Leland Metheny, Amy Moskop, Caron A. Jacobson, Geoffrey Shouse, Sairah Ahmed, Armin Ghobadi, Saurabh Dahiya, Jiali Yan, Zhen-Huan Hu, Timothy Best, Jenny J. Kim, Debbie L. Mirjah, Marcelo C. Pasquini, Frederick L. Locke

Blood (2024) 144 (Supplement 1): 527.

https://doi.org/10.1182/blood-2024-209093

Published: 2024

Journal Articles

Combined Effects of Hematopoietic Cell Transplantation Associated Thrombotic Microangiopathy and Acute Graft-Versus-Host Disease on Requiring Renal Replacement Therapy in US Patient Population - a Secondary CIBMTR Analysis

Udit Nangia, Leland Metheny, Deepak Chandramohan, Hari Naga Garapati, Prathap Simhadri, Neeraj Mahajan

Blood (2024) 144 (Supplement 1): 2154.

https://doi.org/10.1182/blood-2024-208833

Published: 2024

Journal Articles

A Phase II Study of Low Dose Melphalan with Thiotepa and Fludarabine As Preparative Regimen for Alternative Donor Transplantation

Nikki Agarwal, Pingfu Fu, Michael Daunov, Brenda W Cooper, Ben K. Tomlinson, Rebecca B. Klisovic, Marcos de Lima, Folashade Otegbeye, Changchun Deng, Yeritza Hernandez-Collazo, Jignesh Dalal, James Martin, Seunghee Margevicius, James J. Ignatz-Hoover, Ok-Kyong Chaekal, Molly Megan Gallogly, Koen van Besien, Leland Metheny

Blood (2024) 144 (Supplement 1): 2131.

https://doi.org/10.1182/blood-2024-210550

Published: 2024

Journal Articles

A Retrospective Study of C5b-9 and MASP2 Deposition in Skin Microvasculature As a Prognostic and Diagnostic Tool for Transplant-Associated Thrombotic Microangiopathy

Michael Daunov, John Sumodi, Nikki Agarwal, Molly Megan Gallogly, Leland Metheny, Ben K. Tomlinson, Rebecca B. Klisovic, Ali W. Bseiso, Brett Glotzbecker, Kord Honda, Koen van Besien

Blood (2024) 144 (Supplement 1): 2115.

https://doi.org/10.1182/blood-2024-212304

Published: 2024

Journal Articles

Risk Factors for Thrombotic Microangiopathy after Hematopoietic Stem Cell Transplantation By Disease Groups in Competing Risk Analysis

Udit Nangia, Leland Metheny, Neeraj Mahajan

Blood (2024) 144 (Supplement 1): 1239.

https://doi.org/10.1182/blood-2024-202248

Published: 2024

Journal Articles

Effect of Age, Timing of Thrombotic Microangiopathy and Timing of Acute Graft-Versus-Host Disease on Overall Survival after Hematopoietic Stem Cell Transplantation

Udit Nangia, Leland Metheny, Neeraj Mahajan

Blood (2024) 144 (Supplement 1): 3530.

https://doi.org/10.1182/blood-2024-202240

Published: 2024

Journal Articles

A Phase I Clinical Trial of Fully Human Anti-CD19 Chimeric Antigen Receptor T Cells for Relapsed or Refractory Lymphoid Malignancies

Brenda W Cooper, Molly Megan Gallogly, Leland Metheny, Rebecca B. Klisovic, Kirsten Marie Boughan, Jane Reese Koc, Darong Wu, Changchun Deng, Koen Van Besien, Rose Tupta, Dina Schneider, Lisa Ciarrone, Marcos de Lima, Paolo F. Caimi, Benjamin K. Tomlinson

Blood (2023) 142 (Supplement 1): 6872.

https://doi.org/10.1182/blood-2023-191153

Published: 2023

Journal Articles

Vactosertib, a Novel TGFb Type I Receptor Kinase Inhibitor, Improves T-Cell Fitness:a Single-Arm, Phase 1b Trial in Relapsed/Refractory Multiple Myeloma

Ehsan Malek, Priyanka S. Rana, Muthulekha Swamydas, Michael Daunov, Masaru Miyagi, Elena Murphy, James J. Ignatz-Hoover, Leland Metheny, Seong-Jin Kim, James J. Driscoll, II

Blood (2023) 142 (Supplement 1): 4749.

https://doi.org/10.1182/blood-2023-172711

Published: 2023

Journal Articles

African American Race Is a Potential Favorable Biologic Factor That Impacts Clinical Outcome for Patients with Multiple Myeloma

Jeries Kort, Leland Metheny, Pingfu Fu, Shufen Cao, James J. Driscoll, Ehsan Malek

Blood (2022) 140 (Supplement 1): 7244–7245.

https://doi.org/10.1182/blood-2022-170717

Published: 2022

Journal Articles

Circulating Tumor DNA Correlation with Lymphoma Response and Survival Outcomes at Multiple Time Points of Anti - CD19 CAR T Cell Therapy

Paolo F Caimi, Martina Di Trani, Armin Ghobadi, Jane Reese, Benjamin Tomlinson, Folashade Otegbeye, Kirsten M Boughan, Molly Gallogly, Leland Metheny, Brenda W. Cooper, Boro Dropulic, Marcos J.G. de Lima, Carmelo Carlo-Stella

Blood (2022) 140 (Supplement 1): 7457–7459.

https://doi.org/10.1182/blood-2022-170629

Published: 2022

Journal Articles

Multicenter Phase I Study of Post-Transplant Low-Dose Inotuzumab Ozogamicin to Prevent Relapse of Acute Lymphoblastic Leukemia

Leland Metheny, Ronald M. Sobecks, Christina Cho, Jiasheng Wang, Lisa Ciarrone, Paolo F. Caimi, Folashade Otegbeye, Brenda W. Cooper, Molly Gallogly, Ehsan Malek, Aaron T. Gerds, Betty K. Hamilton, Sergio A Giralt, Miguel-Angel Perales, Marcos J.G. de Lima

Blood (2022) 140 (Supplement 1): 1887–1889.

https://doi.org/10.1182/blood-2022-169935

Published: 2022

Journal Articles

Dynamics and Predictive Value of T-Cell Chimerism after Haploidentical Hematopoietic Cell Transplantation Using Post-Transplant Cyclophosphamide

Jiasheng Wang, Benjamin Tomlinson, Ehsan Malek, Leland Metheny, Molly Gallogly, Marcos de Lima, Merle Kolk, Brenda W. Cooper

Blood (2022) 140 (Supplement 1): 12831–12832.

https://doi.org/10.1182/blood-2022-163589

Published: 2022

Journal Articles

PLX-R18 (Avoplacel), a Placental Expanded Mesenchymal-like Stromal Cell Therapy Shows Favorable Safety and Appears to Improve Incomplete Hematopoietic Recovery after Hematopoietic Cell Transplantation (HCT)

Hillard M Lazarus, Joseph P. McGuirk, Tsila Zuckerman, Leland Metheny, Luis Pineiro, Mark R. Litzow, Scott D. Rowley, Batia Avni, Roni Tamari, Michal Sheleg, Daniel Rothenstein, Nitsan Halevy, Jacob M. Rowe

Blood (2022) 140 (Supplement 1): 10447–10448.

https://doi.org/10.1182/blood-2022-169266

Published: 2022

Journal Articles

Safety of Subcutaneous Daratumumab/ Hyaluronidase after Intravenous Daratumumab for Patients with Multiple Myeloma

Melissa Copley, Leland Metheny, Rebecca B. Klisovic, Ehsan Malek

Blood (2022) 140 (Supplement 1): 13202–13203.

https://doi.org/10.1182/blood-2022-162665

Published: 2022

Journal Articles

A Risk Model to Predict the Longitudinal Decline in Creatinine Clearance Among Patients with Precursor Plasma Cell Dyscrasia with Baseline Chronic Kidney Failure

Jeries Kort, Pingfu Fu, Leland Metheny, Ravi Kyasaram, James J. Driscoll, Ehsan Malek

Blood (2022) 140 (Supplement 1): 13176–13177.

https://doi.org/10.1182/blood-2022-162641

Published: 2022

Journal Articles

Multidimensional Quantification of Exclusion Criteria to Reduce the Gap between Randomized Clinical Trial and Real-World Outcomes in Multiple Myeloma

Augusta Eduafo, Leland Metheny, III, Ravi Kyasaram, Farhad Sanati, James J. Driscoll, Ehsan Malek

Blood (2021) 138 (Supplement 1): 4003.

https://doi.org/10.1182/blood-2021-148222

Published: 2021

Journal Articles

Post-Transplant Inotuzumab Ozogamicin for Acute Lymphoblastic Leukemia

Leland Metheny, III, Ronald M. Sobecks, Christina Cho, Paolo F. Caimi, Navneet S. Majhail, Folashade Otegbeye, Kirsten M Boughan, Brenda W. Cooper, Erin Galloway, Molly Gallogly, Ehsan Malek, Benjamin Tomlinson, Aaron T. Gerds, Betty K. Hamilton, Matt Kalaycio, Sergio A Giralt, Marcos J.G. de Lima

Blood (2021) 138 (Supplement 1): 2899.

https://doi.org/10.1182/blood-2021-153041

Published: 2021

Journal Articles

Epigenetic Priming with Pre-Transplant Oral Panobinostat Followed By Post-Transplant Consolidation

Ehsan Malek, Mary Hislop, Leland Metheny, III, Molly Gallogly, Brett Glotzbecker, Steve Stricker, James J. Driscoll

Blood (2021) 138 (Supplement 1): 2917.

https://doi.org/10.1182/blood-2021-151689

Published: 2021

NARROW

Brentuximab vedotin, nivolumab, doxorubicin, and dacarbazine for advanced-stage classical Hodgkin lymphoma

Impact of Timing of Acute Graft-Versus-Host-Disease on Incidence of Thrombotic Microangiopathy after Hematopoietic Stem Cell Transplantation

Real-World Trends of Cytokine Release Syndrome and Neurologic Events, and Pattern of Their Management Among Patients Receiving Axicabtagene Ciloleucel for Relapsed or Refractory (r/r) Large B-Cell Lymphoma (LBCL) in the US: A CIBMTR Report

Combined Effects of Hematopoietic Cell Transplantation Associated Thrombotic Microangiopathy and Acute Graft-Versus-Host Disease on Requiring Renal Replacement Therapy in US Patient Population - a Secondary CIBMTR Analysis

A Phase II Study of Low Dose Melphalan with Thiotepa and Fludarabine As Preparative Regimen for Alternative Donor Transplantation

A Retrospective Study of C5b-9 and MASP2 Deposition in Skin Microvasculature As a Prognostic and Diagnostic Tool for Transplant-Associated Thrombotic Microangiopathy

Risk Factors for Thrombotic Microangiopathy after Hematopoietic Stem Cell Transplantation By Disease Groups in Competing Risk Analysis

Effect of Age, Timing of Thrombotic Microangiopathy and Timing of Acute Graft-Versus-Host Disease on Overall Survival after Hematopoietic Stem Cell Transplantation

A Phase I Clinical Trial of Fully Human Anti-CD19 Chimeric Antigen Receptor T Cells for Relapsed or Refractory Lymphoid Malignancies

Vactosertib, a Novel TGFb Type I Receptor Kinase Inhibitor, Improves T-Cell Fitness:a Single-Arm, Phase 1b Trial in Relapsed/Refractory Multiple Myeloma

African American Race Is a Potential Favorable Biologic Factor That Impacts Clinical Outcome for Patients with Multiple Myeloma

Circulating Tumor DNA Correlation with Lymphoma Response and Survival Outcomes at Multiple Time Points of Anti - CD19 CAR T Cell Therapy

Multicenter Phase I Study of Post-Transplant Low-Dose Inotuzumab Ozogamicin to Prevent Relapse of Acute Lymphoblastic Leukemia

Dynamics and Predictive Value of T-Cell Chimerism after Haploidentical Hematopoietic Cell Transplantation Using Post-Transplant Cyclophosphamide

PLX-R18 (Avoplacel), a Placental Expanded Mesenchymal-like Stromal Cell Therapy Shows Favorable Safety and Appears to Improve Incomplete Hematopoietic Recovery after Hematopoietic Cell Transplantation (HCT)

Safety of Subcutaneous Daratumumab/ Hyaluronidase after Intravenous Daratumumab for Patients with Multiple Myeloma

A Risk Model to Predict the Longitudinal Decline in Creatinine Clearance Among Patients with Precursor Plasma Cell Dyscrasia with Baseline Chronic Kidney Failure

Multidimensional Quantification of Exclusion Criteria to Reduce the Gap between Randomized Clinical Trial and Real-World Outcomes in Multiple Myeloma

Post-Transplant Inotuzumab Ozogamicin for Acute Lymphoblastic Leukemia

Epigenetic Priming with Pre-Transplant Oral Panobinostat Followed By Post-Transplant Consolidation

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only